Marker Therapeutics
MRKR
35 hedge funds and large institutions have $5.84M invested in Marker Therapeutics in 2026 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 4 closing their positions.
15% more capital invested
Capital invested by funds: $5.07M → $5.84M (+$763K)
0.4% more ownership
Funds ownership: 23.41% → 23.81% (+0.4%)
0% more funds holding
Funds holding: 35 → 35 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
14% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$108K |
| 2 |
CIA
Concurrent Investment Advisors
Tampa,
Florida
|
+$99.1K |
| 3 |
Vanguard Capital Management
Malvern,
Pennsylvania
|
+$53.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$47.4K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
+$28.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$63.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$35.3K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$30.7K |
| 4 |
Jane Street
New York
|
-$28.4K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$26.5K |
MRKR Hedge Fund Activity: Q2 2026 in Review
35 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Marker Therapeutics (MRKR) for Q2 2026, worth a combined $5.84M — up 15% from $5.07M a quarter earlier.
Fund positioning in MRKR was balanced in Q2 2026: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 7 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $108K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $63.4K sold.
- 35 institutional investors held Marker Therapeutics (MRKR) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $5.84M of Marker Therapeutics stock for Q2 2026, up 15% quarter-over-quarter.
- 4 funds opened new Marker Therapeutics positions in Q2 2026 and 4 closed out, a net change of 0 holders.
- The largest Marker Therapeutics buyer in Q2 2026 was Renaissance Technologies, an estimated $108K added.
- The largest Marker Therapeutics seller in Q2 2026 was Susquehanna International Group, an estimated $63.4K sold.
Based on aggregated 13F filings for Q2 2026.